Literature DB >> 31366462

The wolf of hypomethylating agent failure: what comes next?

Anne Sophie Kubasch1,2,3, Uwe Platzbecker1,2,3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31366462      PMCID： PMC6669157          DOI： 10.3324/haematol.2019.222794

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  17 in total

Review 1.  Treatment of MDS.

Authors:  Uwe Platzbecker
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

2.  Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.

Authors:  Rami S Komrokji
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

3.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors:  Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

4.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

5.  A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  N Daver; H Kantarjian; F Ravandi; E Estey; X Wang; G Garcia-Manero; E Jabbour; M Konopleva; S O'Brien; S Verstovsek; T Kadia; C Dinardo; S Pierce; X Huang; N Pemmaraju; M Diaz-Pines-Mateo; J Cortes; G Borthakur
Journal:  Leukemia       Date:  2015-09-14       Impact factor: 11.528

6.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

7.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

Authors:  Guillermo Garcia-Manero; Pierre Fenaux; Aref Al-Kali; Maria R Baer; Mikkael A Sekeres; Gail J Roboz; Gianluca Gaidano; Bart L Scott; Peter Greenberg; Uwe Platzbecker; David P Steensma; Suman Kambhampati; Karl-Anton Kreuzer; Lucy A Godley; Ehab Atallah; Robert Collins; Hagop Kantarjian; Elias Jabbour; Francois E Wilhelm; Nozar Azarnia; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2016-03-09       Impact factor: 41.316

8.  A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Authors:  Marie Sébert; Aline Renneville; Cécile Bally; Pierre Peterlin; Odile Beyne-Rauzy; Laurence Legros; Marie-Pierre Gourin; Laurence Sanhes; Eric Wattel; Emmanuel Gyan; Sophie Park; Aspasia Stamatoullas; Anne Banos; Kamel Laribi; Simone Jueliger; Luke Bevan; Fatiha Chermat; Rosa Sapena; Olivier Nibourel; Cendrine Chaffaut; Sylvie Chevret; Claude Preudhomme; Lionel Adès; Pierre Fenaux
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

Review 9.  The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications.

Authors:  Hind Medyouf
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

10.  Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Authors:  Charles F Craddock; Aimee E Houlton; Lynn Swun Quek; Paul Ferguson; Emma Gbandi; Corran Roberts; Marlen Metzner; Natalia Garcia-Martin; Alison Kennedy; Angela Hamblin; Manoj Raghavan; Sandeep Nagra; Louise Dudley; Keith Wheatley; Mary Frances McMullin; Srinivas P Pillai; Richard J Kelly; Shamyla Siddique; Michael Dennis; Jamie D Cavenagh; Paresh Vyas
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531
View more
  2 in total

1.  Development of luspatercept to treat ineffective erythropoiesis.

Authors:  Anne Sophie Kubasch; Pierre Fenaux; Uwe Platzbecker
Journal:  Blood Adv       Date:  2021-03-09

2.  Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.

Authors:  Andrius Zucenka; Kazimieras Maneikis; Birute Pugaciute; Ugne Ringeleviciute; Austeja Dapkeviciute; Linas Davainis; Guoda Daukelaite; Paulina Burzdikaite; Vytautas Staras; Laimonas Griskevicius
Journal:  Ann Hematol       Date:  2021-03-04       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.